Myocardial Hibernation
2002; Lippincott Williams & Wilkins; Volume: 105; Issue: 13 Linguagem: Inglês
10.1161/01.cir.0000014689.12415.89
ISSN1524-4539
AutoresDouglas B. Sawyer, Joseph Loscalzo,
Tópico(s)Cardiovascular Effects of Exercise
ResumoHomeCirculationVol. 105, No. 13Myocardial Hibernation Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBMyocardial HibernationRestorative or Preterminal Sleep? Douglas B. Sawyer, MD, PhD and Joseph Loscalzo, MD, PhD Douglas B. SawyerDouglas B. Sawyer From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass. and Joseph LoscalzoJoseph Loscalzo From the Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Mass. Originally published2 Apr 2002https://doi.org/10.1161/01.CIR.0000014689.12415.89Circulation. 2002;105:1517–1519Oppressed nature sleeps.—Shakespeare, King Lear, Act III, Scene VIThe term hibernating myocardium was first proposed by S. Rahimtoola in 1985 to describe a state of left ventricular dysfunction at rest caused by reduced coronary blood flow, which can be reversed by restoring myocardial oxygen supply or reducing myocardial oxygen demand.1 The clinical context in which it was first recognized, viz, impaired left ventricular function at rest that recovers after revascularization, was refined further when it was recognized that "fixed" defects on [201Tl] perfusion images could improve after revascularization2 or with rest-redistribution3 or reinjection.4 To date, the molecular mechanisms underlying myocardial hibernation have remained elusive.See p 1537Hibernation defines one form of pathophysiological response to myocardial ischemia, the other two being stunning and ischemic preconditioning. Myocardial stunning is defined as ventricular dysfunction that recovers gradually after a brief period of severe ischemia, and ischemic preconditioning is defined as the ability of the myocardium to tolerate an acute ischemic episode with limited ventricular dysfunction as a result of prior brief episodes of ischemia. As one might imagine, these three myocardial responses to ischemia are not mutually exclusive of one another: For example, repetitive stunning superimposed on reduced basal blood flow may contribute to the development of hibernation, and repetitive stunning likely promotes ischemic preconditioning.Hibernation currently is viewed not as a simple consequence of an oxygen deficit, but as an adaptive response to maintain cardiomyocyte viability in the setting of reduced blood flow.5 Characterization of the physiology of hibernation shows that perfusion and contractile function seem to be matched,6 and that myocardial substrate utilization and energy metabolism tend to recover over hours despite active ischemia.7 Reduced calcium responsiveness8 and alterations in adrenergic receptor density9 have been proposed as mechanisms for the decreased contractility. Characteristic ultrastructural changes occur in hibernating human myocardium, including loss of myofibrils, either through degeneration or dedifferentiation of cardiomyocytes, with a loss of mitochondria and increased storage of glycogen.10 Although myocardial necrosis essentially is absent,11 cell loss may occur through programmed cell death, or apoptosis.12In the present issue of Circulation, Kalra and colleagues13 provide evidence that tumor necrosis factor-α (TNF-α) and inducible nitric oxide synthase (iNOS) play a role in mediating myocardial hibernation. In patients undergoing coronary artery bypass surgery, they obtained transmural left ventricular biopsies from dysfunctional or normal myocardial segments as assessed by preoperative dobutamine echocardiography. They extracted the mRNA from these segments and performed reverse transcriptase–polymerase chain reaction using primers for TNF-α and iNOS, and they found dramatic increases in the expression of both of these inducible gene products in dysfunctional segments compared with normal segments. The highest levels of expression of both TNF-α and iNOS were observed in myocardial segments without evidence of contractile reserve as assessed by preoperative dobutamine stress imaging, as well as absence of functional improvement by 3 months after revascularization. Hibernating segments showed levels of expression intermediate to those with normal resting function and those without contractile reserve. There was also a significant correlation between changes in ventricular function 3 months postoperatively and changes in serum TNF-α or nitrite levels, suggesting that the changes in gene expression in myocardial tissue contribute mechanistically to physiological phenotype.These observations support the notion that TNF-α and iNOS cause dose-dependent changes in myocardial dysfunction, with moderate increases leading to reversible myocardial dysfunction, and greater increases contributing to irreversible injury. The negative inotropic effects of TNF-α and the role of iNOS-derived nitric oxide in the control of cardiac function have been well characterized both in vitro and in vivo. TNF-α depresses myocardial contractility by two mechanisms: Within minutes, it causes acute contractile dysfunction by decreasing calcium transients through a sphingosine signaling intermediate14; within hours, it induces iNOS gene expression, which increases nitric oxide production, leading to sustained contractile dysfunction.15 iNOS generates nitric oxide at high flux rates, leading to concentrations in the steady state that are 100- to 1000-fold greater than those produced by endothelial or neuronal NOS. These concentrations of nitric oxide act through a cyclic GMP–dependent mechanism16 to attenuate the cyclic AMP–dependent increase in contractility with β-adrenergic receptor stimulation.17Perhaps more intriguing is the notion that the moderate increases in TNF-α and iNOS in the hibernating myocardium are a requisite part of the adaptive response necessary to maintain myocardial viability in the face of chronically reduced blood flow. Cardiomyocytes increase expression of TNF-α and iNOS after exposure to ischemia-reperfusion and oxidant stress.18,19 TNF-α stimulation has dual effects on mitochondrial function and metabolism via both nitric oxide and the lipid second messenger ceramide. Nitric oxide reversibly decreases mitochondrial respiration by uncoupling oxidative phosphorylation,20 shifts energy substrate utilization from fatty acids to lactate,21 and in the ischemic heart preserves calcium sensitivity and contractile function without an added energy cost.22 Similarly, ceramide also can alter mitochondrial function directly and decrease oxidative phosphorylation.23 Although ceramide can additionally cause release of cytochrome c and activation of apoptotic proteases, this action may be counterbalanced by the inhibitory effect of nitric oxide on these cascades, thereby leading to a form of reversible cell injury, or apoptosis interuptus,24 as observed in hibernating myocardium.TNF-α is a potent stimulus for the expression and activity of the antioxidant mitochondrial enzyme manganese superoxide dismutase (MnSOD), which may play a role in protecting the hibernating myocardium from injury. Through increased mitochondrial formation of reactive oxygen species, MnSOD is upregulated,25 an effect that has been implicated in the delayed preconditioning that occurs after brief ischemia.26 An increase in MnSOD activity presumably would be critical for maintaining low levels of superoxide anion, thereby maintaining the bioavailability of nitric oxide by preventing formation of cytotoxic peroxynitrite.27 In this context, it would be interesting to examine the levels of expression and activity of MnSOD and other antioxidant enzymes in the hibernating myocardium.There is, however, a "dark side" to these local adaptive changes that can promote the development of irreversible myocardial dysfunction. For example, when TNF-α is administered systemically to a rat, there is a sustained decrease in ventricular function and ventricular dilation. Discontinuing the TNF-α treatment after 14 days leads to contractile function recovery; however, ventricular dilation persists.28 More prolonged myocardial exposure to higher levels of TNF-α through transgenic overexpression leads to more severe myocardial injury and dysfunction with changes in myocardial collagen deposition.29 TNF-α may promote scar formation through alterations in interstitial matrix turnover in ischemic myocardium via a transforming growth factor (TGF)-β–dependent mechanism. Recent data suggest that collagen deposition is increased in hibernating myocardium through this mechanism, but to a lesser extent than in irreversibly dysfunctional myocardium.30Although TNF-α and nitric oxide have cytoprotective effects in some contexts, as discussed above, they also can induce myocyte death. Both TNF-α and nitric oxide can promote cardiomyocyte apoptosis: the former by activating the TNF type 1 receptor and the Fas receptor18; the latter by several mechanisms, including the direct production of DNA damage, increases in expression of the tumor suppressor p53, generation of ceramide, selective (ie, cell type–specific) kinase activation, and induction of mitochondrial dysfunction.31 Although TNF-α overexpression alone is sufficient to lead to myocardial injury and increase myocyte apoptosis,29 robust overexpression of iNOS is not.32 This difference in the action of these effectors suggests that the cytotoxicity of iNOS occurs in the context of other stresses—for example, ongoing myocardial ischemia. The ability of iNOS to generate superoxide anion33 (ie, enzyme "uncoupling") and thereby increase cellular oxidative stress under conditions of limited l-arginine or cofactor availability (as might occur in severe ischemia) may also play a role in the cytotoxic effects of iNOS.Taken together, these data suggest that the molecular underpinnings of hibernating myocardium are part of a spectrum of responses to chronic ischemia involving similar effectors. Hibernation stands at one end of the spectrum and irreversible injury at the other. The expression of a specific phenotype at any given time is governed by the magnitude of induction of effectors and their resulting local concentration; the duration of enhanced expression; the presence of pre-existing protective adaptations (eg, ischemic preconditioning, collateral vessel formation); and the presence of pre-existing adverse factors (eg, increased wall stress). It is likely that this spectrum is manifest within a given individual as a continuum, with microenvironments of the chronically ischemic heart containing hibernating cardiomyocytes adjacent to microenvironments containing irreversibly injured cardiomyocytes with extensive apoptosis, necrosis, and scar formation. The question of whether or not exceeding a threshold level of TNF-α or iNOS, or expression of one or more as yet unidentified additional factor(s), is sufficient or necessary for the conversion from reversible to irreversible dysfunction remains unanswered. In addition, the therapeutic implications of these observations are unclear, particularly given that TNF-α and iNOS expression accompany both hibernation and irreversible injury.Like an anesthetic, these endogenous agents that induce hibernation have a narrow toxic-therapeutic window. Exceeding the therapeutic threshold converts the reversible sleep of hibernation into irreversible injury and cell death. What precisely governs this conversion and what effectors may be used to modulate it are important questions that need to be addressed in future studies.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Joseph Loscalzo, MD, PhD, Boston University School of Medicine, Boston, Mass 02118-2394. E-mail [email protected] References 1 Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985; 72(6 Pt 2): V123–V135.Google Scholar2 Berger BC, Watson DD, Burwell LR, et al. Redistribution of thallium at rest in patients with stable and unstable angina and the effect of coronary artery bypass surgery. Circulation. 1979; 60: 1114-1125.CrossrefMedlineGoogle Scholar3 Gewirtz H, Beller GA, Strauss HW, et al. Transient defects of resting thallium scans in patients with coronary artery disease. Circulation. 1979; 59: 707–713.CrossrefMedlineGoogle Scholar4 Dilsizian V, Rocco TP, Freedman NM, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med. 1990; 323: 141–146.CrossrefMedlineGoogle Scholar5 Heusch G, Schulz R. The biology of myocardial hibernation. Trends Cardiovasc Med. 2000; 10: 108–114.CrossrefMedlineGoogle Scholar6 Gallagher KP, Matsuzaki M, Koziol JA, et al. Regional myocardial perfusion and wall thickening during ischemia in conscious dogs. Am J Physiol. 1984; 247: H727–H738.CrossrefMedlineGoogle Scholar7 Arai AE, Pantely GA, Anselone CG, et al. Active downregulation of myocardial energy requirements during prolonged moderate ischemia in swine. Circ Res. 1991; 69: 1458–1469.CrossrefMedlineGoogle Scholar8 Heusch G, Rose J, Skyschally A, et al. Calcium responsiveness in regional myocardial short-term hibernation and stunning in the in situ porcine heart: inotropic responses to postextrasystolic potentiation and intracoronary calcium. Circulation. 1996; 93: 1556–1566.CrossrefMedlineGoogle Scholar9 Shan K, Bick RJ, Poindexter BJ, et al. Altered adrenergic receptor density in myocardial hibernation in humans: a possible mechanism of depressed myocardial function. Circulation. 2000; 102: 2599–2606.CrossrefMedlineGoogle Scholar10 Vanoverschelde JL, Wijns W, Borgers M, et al. Chronic myocardial hibernation in humans: from bedside to bench. Circulation. 1997; 95: 1961–1971.CrossrefMedlineGoogle Scholar11 Schulz R, Guth BD, Pieper K, et al. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery: a model of short-term hibernation. Circ Res. 1992; 70: 1282–1295.CrossrefMedlineGoogle Scholar12 Elsässer A, Schlepper M, Klövekorn WP, et al. Hibernating myocardium, an incomplete adaptation to ischemia. Circulation. 1997; 96: 2920–2931.CrossrefMedlineGoogle Scholar13 Kalra DK, Zhy X, Ramchandani MK, et al. Increased myocardial gene expression of tumor necrosis factor-alpha Aand NOS2: a potential mechanism for depressed myocardial function in hibernating myocardium in man. Circulation. 2002; 105: 1537–1540.LinkGoogle Scholar14 Oral H, Dorn GW2nd, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem. 1997; 272: 4836–4842.CrossrefMedlineGoogle Scholar15 Ungureanu-Longrois D, Balligand JL, Simmons WW, et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to beta-adrenergic agonists. Circ Res. 1995; 77: 494–502.CrossrefMedlineGoogle Scholar16 Vila-Petroff MG, Younes A, Egan J, et al. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res. 1999; 84: 1020–1031.CrossrefMedlineGoogle Scholar17 Keaney JF Jr, Hare JM, Balligand J-L, et al. Inhibition of nitric oxide synthase augments myocardial contractile responses to α-adrenergic stimulation. Am J Physiol. 1996; 271: H2646–H2652.MedlineGoogle Scholar18 Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol. 1998; 274: R577–R595.CrossrefMedlineGoogle Scholar19 Kan H, Xie Z, Finkel MS. TNF-alpha enhances cardiac myocyte NO production through MAP kinase-mediated NF-kappaB activation. Am J Physiol. 1999; 277(4 Pt 2): H1641–H1646.Google Scholar20 Xie YW, Shen W, Zhao G, et al. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro: implications for the development of heart failure. Circ Res. 1996; 79: 381–387.CrossrefMedlineGoogle Scholar21 Recchia FA, McConnell PI, Bernstein RD, et al. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res. 1998; 83: 969–979.CrossrefMedlineGoogle Scholar22 Heusch G, Post H, Michel MC, et al. Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res. 2000; 87: 146–152.CrossrefMedlineGoogle Scholar23 Di Paola M, Cocco T, Lorusso M. Ceramide interaction with the respiratory chain of heart mitochondria. Biochemistry. 2000; 39: 6660–6668.CrossrefMedlineGoogle Scholar24 Narula J, Arbustini E, Chandrashekhar Y, et al. Apoptosis and the systolic dysfunction in congestive heart failure: story of apoptosis interruptus and zombie myocytes. Cardiol Clin. 2001; 19: 113–126.CrossrefMedlineGoogle Scholar25 Liu R, Buettner GR, Oberley LW. Oxygen free radicals mediate the induction of manganese superoxide dismutase gene expression by TNF-alpha. Free Radic Biol Med. 2000; 28: 1197–1205.CrossrefMedlineGoogle Scholar26 Yamashita N, Hoshida S, Otsu K, et al. The involvement of cytokines in the second window of ischaemic preconditioning. Br J Pharmacol. 2000; 131: 415–422.CrossrefMedlineGoogle Scholar27 Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271(5 Pt 1): C1424–C1437.Google Scholar28 Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998; 97: 1382–1391.CrossrefMedlineGoogle Scholar29 Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998; 97: 1375–1381.CrossrefMedlineGoogle Scholar30 Elasser A, Decker E, Kostin S, et al. A self-perpetuating vicious cycle of tissue damage in human hibernating myocardium. Mol Cell Biochem. 2000; 213: 17–28.CrossrefMedlineGoogle Scholar31 Kim PK, Zamora R, Petrosko P, et al. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol. 2001; 1: 1421–1441.CrossrefMedlineGoogle Scholar32 Heger J, Godecke A, Flogel U, et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res. 2002; 90: 93–99.CrossrefMedlineGoogle Scholar33 Xia Y, Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci U S A. 1997; 94: 6954–6958.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Xiao F, Wang D, Kong L, Li M, Feng Z, Shuai B, Wang L, Wei Y, Li H, Wu S, Tan C, Zhao H, Hu X, Liu J, Kang Y, Liao X, Zhou Y and Zhang W (2018) Intermedin protects against sepsis by concurrently re-establishing the endothelial barrier and alleviating inflammatory responses, Nature Communications, 10.1038/s41467-018-05062-2, 9:1, Online publication date: 1-Dec-2018. Gewirtz H and Dilsizian V (2017) Myocardial Viability, Circulation Research, 120:7, (1197-1212), Online publication date: 31-Mar-2017. Schaalan M and Mohamed W (2016) Determinants of hepcidin levels in sepsis-associated acute kidney injury: Impact on pAKT/PTEN pathways?, Journal of Immunotoxicology, 10.1080/1547691X.2016.1183733, 13:5, (751-757), Online publication date: 2-Sep-2016. Krüger W and Ludman A (2014) Sepsis Core Knowledge in Critical Care Medicine, 10.1007/978-3-642-54971-7_4, (273-312), . Morrell E, Kellum J, Pastor-Soler N and Hallows K (2014) Septic acute kidney injury: molecular mechanisms and the importance of stratification and targeting therapy, Critical Care, 10.1186/s13054-014-0501-5, 18:5, Online publication date: 1-Oct-2014. Sim D, Jeong M, Ahn Y, Kim Y, Chae S, Hong T, Seong I, Chae J, Kim C, Cho M, Rha S, Bae J, Seung K and Park S (2012) Benefit of Percutaneous Coronary Intervention in Early Latecomers With Acute ST-Segment Elevation Myocardial Infarction, The American Journal of Cardiology, 10.1016/j.amjcard.2012.06.028, 110:9, (1275-1281), Online publication date: 1-Nov-2012. Fontanelli A and Bonanno C (2011) Primary percutaneous coronary intervention in 'early' latecomers with ST-segment elevation acute myocardial infarction: the role of the infarct-related artery status, Journal of Cardiovascular Medicine, 10.2459/JCM.0b013e32834038d8, 12:1, (13-18), Online publication date: 1-Jan-2011. Flierl M, Rittirsch D, Huber-Lang M, Sarma J and Ward P (2008) Molecular Events in the Cardiomyopathy of Sepsis, Molecular Medicine, 10.2119/2007-00130.Flierl, 14:5-6, (327-336), Online publication date: 1-May-2008. Parodi G, Ndrepepa G, Kastrati A, Conti A, Mehilli J, Sciagrà R, Schwaiger M, Antoniucci D and Schømig A (2006) Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms, American Heart Journal, 10.1016/j.ahj.2006.08.007, 152:6, (1133-1139), Online publication date: 1-Dec-2006. Heusch G, Schulz R and Rahimtoola S (2005) Myocardial hibernation: a delicate balance, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.01109.2004, 288:3, (H984-H999), Online publication date: 1-Mar-2005. Salazar H and Talano J (2005) Viable Myocardium: How Much Is Enough?. A Comparison of Viability by Comparative Imaging Techniques to Assess the Quantity and Functionality of Ischemic Myocardium, Echocardiography, 10.1111/j.0742-2822.2005.04029.x, 22:1, (59-70), Online publication date: 1-Jan-2005. Bumbasirevic V, Karamarkovic A, Lesic A and Bumbasirevic M (2005) Trauma-related sepsis and multiple organ failure: Current concepts in the diagnosis and management, Current Orthopaedics, 10.1016/j.cuor.2005.05.006, 19:4, (314-321), Online publication date: 1-Aug-2005. Kosmala W, Przewlocka-Kosmala M and Mazurek W (2005) Proinflammatory cytokines and myocardial viability in patients after acute myocardial infarction, International Journal of Cardiology, 10.1016/j.ijcard.2004.03.067, 101:3, (449-456), Online publication date: 1-Jun-2005. Taylor A, Al-Saadi N, Abdel-Aty H, Schulz-Menger J, Messroghli D and Friedrich M (2004) Detection of Acutely Impaired Microvascular Reperfusion After Infarct Angioplasty With Magnetic Resonance Imaging, Circulation, 109:17, (2080-2085), Online publication date: 4-May-2004. Hörner C, Bouchon A, Bierhaus A, Nawroth P, Martin E, Bardenheuer H and Weigand M (2004) Bedeutung der angeborenen Immunantwort in der Sepsis, Der Anaesthesist, 10.1007/s00101-003-0626-4, 53:1, (10-28), Online publication date: 1-Jan-2004. Westaby S (2004) Coronary revascularization in ischemic cardiomyopathy, Surgical Clinics of North America, 10.1016/S0039-6109(03)00207-X, 84:1, (179-199), Online publication date: 1-Feb-2004. Basso C, Valente M and Thiene G (2003) "Hibernating" Myocardium: Not Only a Matter of Semantics, Circulation, 107:1, (e10-e10), Online publication date: 7-Jan-2003. Hotchkiss R and Karl I (2003) The Pathophysiology and Treatment of Sepsis, New England Journal of Medicine, 10.1056/NEJMra021333, 348:2, (138-150), Online publication date: 9-Jan-2003. Sasayama S (2003) Immunomodulation in Heart Failure: Experimental Models Inflammation and Cardiac Diseases, 10.1007/978-3-0348-8047-3_13, (203-219), . Abbate A, Biondi-Zoccai G and Baldi A (2002) Pathophysiologic role of myocardial apoptosis in post-infarction left ventricular remodeling, Journal of Cellular Physiology, 10.1002/jcp.10174, 193:2, (145-153), Online publication date: 1-Nov-2002. Mohammadzadeh A, Maleki Z, Nahardani A and Mohammadzadeh M (2018) Correlations of T2* Mapping with Delayed Gadolinium Enhancement in Chronic Myocardial Infarction Magnetic Resonance Imaging, Iranian Journal of Radiology, 10.5812/iranjradiol.12688, In Press:In Press April 2, 2002Vol 105, Issue 13 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000014689.12415.89PMID: 11927510 Originally publishedApril 2, 2002 Keywordsmyocardial contractionEditorialsnitric oxide synthaseventricleshibernationPDF download Advertisement
Referência(s)